Evidence map›Paper›PMID 32577620›Full record

ArticleJournal of cancer research and cellular therapeutics2019

The Tale of CHD4 in DNA Damage Response and Chemotherapeutic Response.

Jing Zhang, David J H Shih, Shiaw-Yih Lin

Open access · diamondAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of cancer research and cellular therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. CHD4 and NOX4 expression in thyroid tumor tissues.Exploration of targeted anti-tumor therapy · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jing ZhangDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
David J H ShihDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Shiaw-Yih LinDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Characterizing and Targeting CHD4 Deficiency in Endometrial CancerR01CA172490 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, SHIAW-YIH · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA172490
6 · The paper itself

Abstract

The chromatin remodeling factor chromodomain helicase DNA-binding protein 4 (CHD4) is a core component of the nucleosome remodeling and deacetylase (NuRD) complex. Due to its important role in DNA damage repair, CHD4 has been identified as a key determinant in cancer progression, stem cell differentiation, and T cell and B cell development. Accumulating evidence has revealed that CHD4 can function in NuRD dependent and independent manner in response to DNA damage. Mutations of CHD4 have been shown to diminish its functions, which indicates that interpretation of its mutations may provide tangible benefit for patients. The expression of CHD4 play a dual role in sensitizing cancer cells to chemotherapeutic agents, which provides new insights into the contribution of CHD4 to tumor biology and new therapeutic avenues.

Indexed as

CHD4chemotherapeutic responseDNA damage responsemutations

Identifiers

PMID32577620
PMCPMC7310990
OpenAlexW3037390437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.